Evidence map›Paper›PMID 24997444›Full record

ReviewCurrent opinion in biotechnology2014

Exploiting the proteomics revolution in biotechnology: from disease and antibody targets to optimizing bioprocess development.

Kelley M Heffner, Deniz Baycin Hizal, Amit Kumar, Joseph Shiloach, Jie Zhu, Michael A Bowen, Michael J Betenbaugh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kelley M HeffnerChemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Deniz Baycin HizalAntibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, MD, USA.
Amit KumarChemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, MD, USA.
Joseph ShiloachNational Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, MD, USA.
Jie ZhuAntibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, MD, USA.
Michael A BowenAntibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, MD, USA.
Michael J BetenbaughChemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.

Funding

Identification of genes related to spcific properties of mammalian cellsZIADK075080 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 2012 to 2022
$5.0M
Identification of genes realted to spcific properties of mammlian cellsZ01DK070010 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 2007 to 2008
$568k
Intramural NIH HHS Z01 DK070010
6 · The paper itself

Abstract

Recent advancements in proteomics have enabled the generation of high-quality data sets useful for applications ranging from target and monoclonal antibody (mAB) discovery to bioprocess optimization. Comparative proteomics approaches have recently been used to identify novel disease targets in oncology and other disease conditions. Proteomics has also been applied as a new avenue for mAb discovery. Finally, CHO and Escherichia coli cells represent the dominant production hosts for biopharmaceutical development, yet the physiology of these cells types has yet to be fully established. Proteomics approaches can provide new insights into these cell types, aiding in recombinant protein production, cell growth regulation, and medium formulation. Optimization of sample preparations and protein database developments are enhancing the quantity and accuracy of proteomic results. In these ways, innovations in proteomics are enriching biotechnology and bioprocessing research across a wide spectrum of applications.

Indexed as

AnimalsBiotechnologyCHO CellsCricetulusEscherichia coliProteomics

Identifiers

PMID24997444
PMCPMC9536114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.